<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025272</url>
  </required_header>
  <id_info>
    <org_study_id>REBACDR0000068945</org_study_id>
    <secondary_id>CCCWFU-62300</secondary_id>
    <secondary_id>NCI-5333</secondary_id>
    <nct_id>NCT00025272</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Study of Sequential Topotecan-Carboplatin-Etoposide in Patients With Extensive Stage Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug and giving them in different ways may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining topotecan, carboplatin, and&#xD;
      etoposide in treating patients who have extensive-stage small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxicity profile and maximum tolerated dose of sequential topotecan,&#xD;
           carboplatin, and etoposide in patients with chemotherapy-naive extensive stage small&#xD;
           cell lung cancer. (Phase I closed to accrual as of 04/04/2003).&#xD;
&#xD;
        -  Determine the response rate and duration of response in patients with treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the failure-free and overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the pharmacokinetics and pharmacodynamics of topotecan and etoposide on this&#xD;
           schedule in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study of topotecan and etoposide. (Phase I&#xD;
      closed to accrual as of 04/04/2003).&#xD;
&#xD;
      Patients receive oral topotecan on days 1-5, carboplatin IV over 30 minutes on day 6, and&#xD;
      oral etoposide on days 6-10. Treatment continues every 3 weeks for 2 courses in the absence&#xD;
      of disease progression or unacceptable toxicity. Patients with complete response (CR) or&#xD;
      partial response after the second course receive up to 4 additional courses. Patients with&#xD;
      brain metastases at initial presentation undergo whole-brain irradiation before the&#xD;
      chemotherapy regimen. Patients without brain metastases at initial presentation who achieve&#xD;
      CR undergo prophylactic whole-brain irradiation.&#xD;
&#xD;
      Sequential dose escalation of topotecan is followed by sequential dose escalation of&#xD;
      etoposide. Cohorts of 3-6 patients receive escalating doses of topotecan and then etoposide&#xD;
      until the maximum tolerated dose (MTD) of the combination is determined. The MTD is defined&#xD;
      as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting&#xD;
      toxicity. (Phase I closed to accrual as of 04/04/2003). In the phase II part of study, an&#xD;
      additional 11-40 patients are accrued to receive topotecan, carboplatin, and etoposide at the&#xD;
      MTD.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 50 patients (3-10 for phase I and 11-40 for phase II) will be&#xD;
      accrued for this study. (Phase I closed to accrual as of 04/04/2003)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2001</start_date>
  <completion_date type="Actual">January 18, 2005</completion_date>
  <primary_completion_date type="Actual">January 18, 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure-free and overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics and pharmacodynamics of topotecan and etoposide</measure>
  </secondary_outcome>
  <enrollment type="Actual">14</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>topotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed extensive stage small cell lung cancer&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
               -  Pleural effusions allowed, but not considered measurable or evaluable disease&#xD;
&#xD;
          -  Brain metastases allowed provided neurologically stable at study entry&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 2 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Able to swallow capsules&#xD;
&#xD;
          -  No concurrent or prior malignancy within the past 5 years except inactive&#xD;
             nonmelanomatous skin cancer or carcinoma in situ of the cervix&#xD;
&#xD;
          -  No other serious medical or psychiatric illness that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Prior radiotherapy for brain metastasis allowed&#xD;
&#xD;
          -  No other prior radiotherapy&#xD;
&#xD;
          -  No other concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonius A. Miller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534-9479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Greenville</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBCCOP - Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>extensive stage small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

